Digital medication management company MedAdvisor Ltd (ASX: MDR) last week announced it has raised $17 million by issuing 340 million new shares at an issue price of 5 cents per share. That actually represented an 11% premium to its last pre-cap raising trading price of 4.5 cents per share.
Nasdaq-listed US healthcare operator HMS Holdings Corp (HMSY) is a cornerstone investor in the capital raising by agreeing to tip in $11 million.
“Funds raised will accelerate international expansion through MedAdvisor’s synergistic partnering strategies in the US, South East Asia and the UK, as well as driving domestic growth through sales, marketing and technology development taking the business towards cash break even,” Medadvisor reported.
As part of the deal MedAdvisor also reports it will become HMS’s “preferred partner” for the distribution of digital health software-as-a-service products in the US and Australia.
MedAdvisor claims to have connected more than 1 million patients already via a network of around 55% of all Australian pharmacies.
For the fiscal year ending June 30 2019 it reported a net loss of $8.15 million on sales of $8.24 million and total revenue of $9.2 million.
It recently recruited the ex Redbubble Ltd (ASX: RBL) chief technology officer to take up the role at MedAdvisor.
As at September 2 2019 it had 1.37 billion shares on issue, with another 340 million issued as a result of the capital raising. As a result it looks to have a market value around $85 million based on around 1.71 billion shares on issue.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has recommended MedAdvisor and REDBUBBLE FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm